SHUKLA SANJAY (President and CEO) purchased 13.7% of their position (2.50K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $21.4K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 11/15/2021ACC: 0001209191-21-064565
Officer· President and CEO
Since Feb 2019
+2.50K
Net shares
Net buyer
$21.4K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
2.50K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+2.50K
Price / share
$8.57
Trade value
$21.44K
% of position
13.7%
11/15/2021
18.30K→20.80K
Total
Net shares
+2.50K
Net value
$21.44K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/15/2021 | P · Purchase | +2.50K | $8.57 | $21.44K | 13.7% | 18.30K | 20.80K |
| Total | +2.50K | $21.44K | ||||||
Derivative Transactions0
No derivative transactions reported